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A detailed understanding of the processes governing adipose tissue formation will be instrumental in combating the obesity
epidemic. Much progress has been made in the last two decades in defining transcriptional events controlling the differen-
tiation of mesenchymal stem cells into adipocytes. A complex network of transcription factors and cell-cycle regulators, in
concert with specific transcriptional coactivators and corepressors, respond to extracellular stimuli to activate or repress
adipocyte differentiation. This review summarizes advances in this field, which constitute a framework for potential antiobe-
sity strategies.Introduction
Obese individuals are more likely than their lean counterparts
to develop cardiovascular disease and type 2 diabetes. The in-
crease in adiposity in these individuals results from an upsurge
in both adipocyte number and size of individual fat cells. Addi-
tionally, the disproportionate increase in the visceral adipose
depots in some individuals is linked to development of certain
metabolic disorders. Consequently, understanding the mecha-
nisms regulating adipose formation should provide valuable in-
formation in the fight to combat the growing incidence of obesity
in the modern world.
During the last several years, investigators have embarked on
a detailed and systematic endeavor to define the transcriptional
events regulating preadipocyte differentiation (adipogenesis)
and adipocyte function. The differentiation of preadipocytes
into adipocytes is regulated by an elaborate network of tran-
scription factors that coordinate expression of hundreds of pro-
teins responsible for establishing the mature fat-cell phenotype.
At the center of this network are the two principal adipogenic
factors, PPARg and C/EBPa, which oversee the entire terminal
differentiation process. PPARg in particular is considered the
master regulator of adipogenesis; without it, precursor cells are
incapable of expressing any known aspect of the adipocyte
phenotype (Rosen et al., 2002). On the other hand, cells deficient
in C/EBPa are capable of adipocyte differentiation; however,
these C/EBPa-deficient cells are insulin resistant (El-Jack
et al., 1999;Wu et al., 1999). Much of our knowledge of this com-
plex network and the importance of PPARg and C/EBPa comes
from studies performed in established preadipocyte cell lines
as well as mesenchyme-derived precursor cells. More recently,
data from a variety of knockout mice have confirmed these
in vitro studies showing that many components of this network
are required regulators of adipocyte development and function.
The 3T3-L1 and 3T3-F422A preadipocyte cell lines originally
established by Green and associates have greatly facilitated
our knowledge of the molecular mechanisms controlling adipo-
genesis (Green and Kehinde, 1975, 1976). Although committed
to the adipocyte lineage, proliferating 3T3-L1 preadipocytes
exert characteristics similar to those of other 3T3 fibroblasts.
Confluent 3T3-L1 preadipocytes differentiate upon exposure
to the adipogenic inducers fetal bovine serum (FBS), dexameth-
asone, isobutylmethylxanthine, and insulin. This cocktail acti-
vates an adipogenic program, which occurs in two well-definedCELL METABOLISM 4, 263–273, OCTOBER 2006 ª2006 ELSEVIER INCphases. The stimulated cells immediately reenter the cell cycle
and progress through at least two cell-cycle divisions, a phase
often referred to as clonal expansion. During this time, the cells
express specific adipogenic transcription factors as well as cell-
cycle regulators that together facilitate expression of PPARg
and C/EBPa. Following this event, the committed cells undergo
terminal differentiation manifested by production of lipid drop-
lets as well as expression of multiple metabolic programs char-
acteristic of mature fat cells. The validity of this 3T3-L1 system
as an appropriate model of adipocyte formation in the animal
has been supported by many studies performed in both mouse
and human tissue.
The goal of this review is to discuss the transcriptional pro-
cesses controlling the conversion of progenitor mesenchymal
cells into fully functional adipocytes. Emphasis will be given to
the transcription factors that have been shown to respond to
various effectors and that induce a well-defined component of
the adipogenic process. A number of factors attenuate adipo-
genesis and serve to function as molecular switches in control-
ling the fate of the progenitors; consequently, the mechanisms
by which these negative regulators inhibit the activity of the
proadipogenic factors will be discussed. Finally, the review will
conclude with a discussion of the recent advances in our under-
standing of how various coactivators and corepressors control
the activity of the adipogenic transcription factors and facilitate
their communication with the transcriptional machinery.
Elucidation of the network of transcription
factors regulating adipogenesis
PPARg and C/EBPa: master regulators of adipogenesis
The role of PPARg as the master regulator of adipogenesis is
supported by overwhelming evidence from both in vivo and
in vitro studies. Important early evidence of the critical role of
PPARg in regulating adipogenesis came from Spiegelman and
collaborators, who had worked for several years to elucidate
the transcription factors regulating expression of the adipose-
specific fatty acid binding protein aP2/FABP4. This endeavor
resulted in identification of a nuclear factor initially referred to
as ARF6 that was later shown through cloning technology to
correspond to PPARg and its heterodimeric partner, RXR (Ton-
tonoz et al., 1994a, 1994b). A series of gain-of-function studies
in which pparg was ectopically expressed in nonadipogenic
mouse fibroblasts showed that PPARg alone can initiate the. DOI 10.1016/j.cmet.2006.07.001 263
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ble of many of the functions of mature adipocytes (Tontonoz
et al., 1994c). In attempting to understand the importance of
PPARg in the development of adipocytes, investigators found
that ablation of pparg in embryonic stem (ES) cells leads to em-
bryonic lethality at E10 due to a defect in placentation as a result
of PPARg’s participation in formation of the trophoblast (Barak
et al., 1999). To circumvent this problem, alternative strategies
for obtaining knockout mice were developed that supported
a role for PPARg in the formation of all fat depots, including
both brown and white (Barak et al., 1999; Rosen et al., 1999).
Thesemousemodels, however, providedonly partial information
concerning the function of PPARg in adipocytes since both
models were subject to significant limitations. In one case, the
conclusionswere based on chimericmice derived fromhomozy-
gously targeted ES cells (Rosen et al., 1999). In these animals,
the knockout cells failed to develop into adipocytes; whereas
the wild-type-derived cells gave rise to fully functioning adipose
depots. Consequently, it was difficult to assess what impact the
absenceof PPARghasonadipose tissue function. The tetraploid
embryo strategy of Evans and coworkers (Barak et al., 1999)
generated only one mouse, which died soon after birth, but
allowed these investigators to observe that PPARg deficiency
in these animals resulted in failure to formadipose tissue. The es-
tablishment of white adipose tissue (WAT)-hypomorphic pparg
knockdown mice resulted in animals that were severely lipody-
strophic; these data authenticate PPARg as themaster regulator
of adipogenesis (Koutnikova et al., 2003).
pparg is expressed as two isoforms, pparg1 and pparg2, gen-
erated by alternative promoter usage of the same gene, which
gives rise to four distinct mRNAs. pparg1, pparg3, and pparg4
mRNAs all encode the PPARg1 polypeptide, while pparg2
mRNA encodes the corresponding PPARg2 polypeptide, which
is identical to PPARg1 with an additional 30 amino acids present
at the N terminus (Fajas et al., 1997; Meirhaeghe et al., 2003;
Tontonoz et al., 1994b). PPARg1 is expressed in many tissues,
whereas PPARg2 expression is restricted almost exclusively
to adipose. Studies performed in pparg2/2mouse embryonic fi-
broblasts (MEFs) demonstrate that ectopic PPARg1 is as capa-
ble of inducing adipogenesis as PPARg2 (Mueller et al., 2002).
Furthermore, adipose-selective knockout of pparg2 in the
mouse gives rise to insulin-insensitive animals with reduced
fat; however, they still contain substantial amounts of adipose
tissue, suggesting that PPARg1 can compensate for many of
the adipogenic functions of PPARg2 (Zhang et al., 2004a). The
fact that the PPARg2-deficient mice are insulin resistant sug-
gests that PPARg2 may play a selective role in regulating insulin
sensitivity.
Recognition that C/EBPa functions as a principal player in adi-
pogenesis also resulted fromgain-of-function studies in cultured
cells as well as establishment of appropriate knockout mice. In
the former case, Freytag and associates demonstrated that ec-
topic expression of C/EBPa in a variety of fibroblastic cells could
induce adipogenesis (Freytag et al., 1994). Similar to the PPARg
studies, establishment of C/EBPa knockout mice was subject to
significant setbacks since the animals die soon after birth due to
the pups’ inability to produce glucose. This phenotype results
from the requirement of C/EBPa for gluconeogenesis in the liver
(Wang et al., 1995). Ablation of c/ebpa in all tissues except the
liver revealed thatC/EBPa is required for formationofWAT. Inter-
estingly, C/EBPa is not required for the formation of brown264adipose tissue (BAT), an observation that currently is not under-
stood (Linhart et al., 2001).
PPARg can induce adipogenesis in C/EBPa-deficient MEFs,
whereas C/EBPa is incapable of driving the adipogenic program
in the absence of PPARg (Rosen et al., 2002). This observation
suggests that C/EBPa and PPARg participate in a single path-
way of adipose development, in which PPARg is the dominant
factor. It must be mentioned that C/EBPa does provide a critical
function during terminal adipogenesis since failure to express
C/EBPa results in insulin resistance in cell culture models and
an inability to develop WAT in vivo (El-Jack et al., 1999; Linhart
et al., 2001; Wu et al., 1999). It has been suggested that, in ad-
dition to controlling insulin action, C/EBPa is required for main-
taining expression of PPARg in the mature fat cell (Wu et al.,
1999). It is possible that establishment of the adipogenic pheno-
type in C/EBPa-deficient brown adipocytes is due to other
mechanisms (possibly other C/EBPs) that function to maintain
PPARg production.
C/EBPb and C/EBPd
Well before the discovery of PPARg as the master regulator of
adipogenesis, several investigators attempted to identify the
mechanisms responsible for determining the differentiation
of precursor cells into adipocytes. It is now established that a
cascade of transcription factors eventually leads to expression
of PPARg and C/EBPa. The first indication of such a network
came from the work of McKnight and associates, which sug-
gested that two other members of the C/EBP family, C/EBPb
and C/EBPd, are expressed earlier than C/EBPa during adipo-
genesis in 3T3-L1 cells and that they are responsible for regulat-
ing C/EBPa expression (Cao et al., 1991; Yeh et al., 1995). Spe-
cifically, they demonstrated that ectopic expression of C/EBPb
and C/EBPd in 3T3-L1 preadipocytes induces C/EBPa expres-
sion and the adipogenic program in the absence of extracellular
hormones. They also showed that introduction of these C/EBPs
into nonadipogenic NIH 3T3 fibroblasts can induce adipogene-
sis without stimulating C/EBPa expression.
These studies did not address, however, the mechanisms
regulating PPARg production. Other studies aimed at identifying
the early events regulating adipogenesis demonstrated a direct
link between the C/EBPs and PPARg. Specifically, ectopic ex-
pression of C/EBPb in NIH 3T3 fibroblasts, alone or in combina-
tion with C/EBPd, induces expression of PPARg2 and, following
exposure to PPARg ligands, in doing so, facilitates the conver-
sion of the cells into adipocytes (Wu et al., 1995, 1996). In agree-
ment with McKnight et al., these studies showed that NIH 3T3
cells do not express C/EBPa, even though they accumulate
abundant amounts of triglyceride in response to activation of
PPARg. Additionally, both groups observed that C/EBPd alone
possesses minimal adipogenic activity. C/EBPb and C/EBPd
play important roles in inducing expression of C/EBPa and
PPARg. This was shown by the identification of functional
C/EBP regulatory elements in the promoters of c/ebpa and
pparg (Christy et al., 1991; Clarke et al., 1997).
In an attempt to define the sequence of events leading to ter-
minal adipogenesis, it was proposed that C/EBPb and C/EBPd
simultaneously control expression of both PPARg and C/EBPa.
Alternatively, some investigators have suggested that C/EBPb
induces C/EBPa and that, together, these factors regulate
PPARg expression. More recently, studies have shown that
ectopic expression of C/EBPb in Swiss fibroblasts induces
PPARg as expected but is incapable of inducing C/EBPa toCELL METABOLISM : OCTOBER 2006
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Moreover, retroviral expression of C/EBPb in pparg2/2 MEFs
also shows that C/EBPb, in the absence of active PPARg, is in-
capable of stimulating expression of c/ebpa (Zuo et al., 2006). It
appears, therefore, that the principal pathway of adipogenesis
involves induction of C/EBPb and C/EBPd, which then facilitate
expression of PPARg. PPARg along with these C/EBPs then
activates C/EBPa expression.
The precise role of C/EBPb and C/EBPd in regulating this cas-
cade of factors has been questioned, however, in knockout
mice. Specifically, Tanaka et al. (1997) demonstrated that neo-
natal mice lacking both C/EBPb and C/EBPd have a defect in
their ability to produce adipose tissue; however, this defect ap-
pears to be downstream of both PPARg and C/EBPa since both
factors are expressed in the poorly differentiated adipose tissue.
In contrast, MEFs obtained from these knockout mice do not ex-
press C/EBPa or PPARg and are incapable of undergoing adi-
pogenesis in culture when compared to wild-type cells. These
data suggest that there is some redundancy in the early steps
of adipogenesis in vivo where alternative pathways operate to
ensure expression of PPARg and C/EBPa. Furthermore, it ap-
pears that C/EBPb and C/EBPd, in addition to inducing expres-
sion of PPARg and C/EBPa, provide other functions during
terminal adipogenesis since their absence prevents terminal
adipogenesis at a step downstream of PPARg or C/EBPa.
One possible function might include induction of programs re-
sponsible for production of PPARg ligands (Hamm et al., 2001).
Identifying the factors that regulate C/EBPb and C/EBPd ex-
pression as well as cooperate with these C/EBPs in an adipo-
genic-specific manner should provide additional insight into
the mechanisms regulating the commitment of mesenchymal
stem cells to the adipogenic lineage. Studies from Klemm and
Lane provide convincing evidence that the cAMP regulatory el-
ement-binding protein, CREB, which is activated very early dur-
ing adipogenesis in 3T3-L1 cells, participates in the induction of
C/EBPb expression (Zhang et al., 2004b). This observation is
consistent with earlier studies showing a role for cAMP signaling
in controlling C/EBPb expression (Cao et al., 1991) and also
explains the need for inducers of cAMP (isobutylmethylxanthine)
in cocktails that initiate the adipogenic program. In contrast, in-
duction of C/EBPd is facilitated by glucocorticoids and C/EBPb
(Cao et al., 1991).
Other adipogenic factors
Recent quantitative expression profiling utilizing both microar-
ray and qPCR analysis of mRNAs expressed during the early
phase of adipogenesis in vitro and in adipose tissue in vivo sug-
gests that many additional transcription factors are potential
components of this complex network of factors responsible
for inducing adipogenic gene expression (Fu et al., 2005b; Sou-
kas et al., 2001). Investigators have identified Krox20 as a factor
that acts early in the adipogenic program and appears to con-
tribute to induction of C/EBPb expression. Krox20 (also known
as early growth response gene 2, or Egr2) is a transcription fac-
tor that is induced immediately following exposure of cells to
mitogens. Krox20 is activated early in the adipogenic program
of 3T3-L1 cells and not only promotes expression of C/EBPb
but also cooperates with C/EBPb to facilitate terminal adipogen-
esis (Chen et al., 2005).
The fact that these early events, including activation of CREB,
Krox20, and C/EBPb, precede induction of PPARg and C/EBPa
transcription by 1 to 2 days suggests that additional processesCELL METABOLISM : OCTOBER 2006are required in order to facilitate terminal adipogenesis. Lane
and associates, in an attempt to explain this lag, suggested
that C/EBPb does not attain the capacity to bind to C/EBP re-
sponse elements in the promoters of its target genes until sev-
eral hours after its appearance in the nucleus because it is
bound to satellite DNA (Tang and Lane, 1999). They proposed
that its release from this compartment is facilitated by changes
in chromatin structure that occur during clonal expansion and
terminal adipogenesis. More recently, these investigators sug-
gested that this lag in C/EBPb activity also results from a delay
in its phosphorylation by MAPKs and GSK3, which is required
for its DNA-binding activity (Tang et al., 2005). Other studies
have also identified an important site of phosphorylation within
a regulatory domain of C/EBPb, but, unlike the studies of
Lane, these studies suggest that phosphorylation regulates
C/EBPa expression (Park et al., 2004). More recent investiga-
tions suggest that the lag between the appearance of C/EBPb
and the expression of PPARg2 results from the time required
for synthesis of additional proteins that facilitate the activity of
C/EBPb. Specifically, transcription of the Kruppel-like factor
KLF5 is activated by C/EBPb and C/EBPd and, in concert with
these C/EBPs, contributes to induction of PPARg2 (Oishi
et al., 2005). Neonatal heterozygous KLF5 knockout mice have
a significant deficiency in adipose tissue formation (Oishi
et al., 2005). Additionally, MEFs obtained from these KLF5+/2
mice are compromised in their ability to undergo adipogenesis
in culture. Studies also suggest a role for other members of
the KLF family including KLF6 and KLF15 in promoting adipo-
genesis (Li et al., 2005; Mori et al., 2005).
It is likely that additional factors of parallel pathways are in-
duced early and converge on PPARg at a stage downstream
of C/EBPb and C/EBPd, such as the helix-loop-helix (HLH) tran-
scription factor SREBP1c/ADD-1. A potential role for SREBP1c
in regulating adipogenesis derives from studies showing that its
expression is significantly enhanced in 3T3-L1 adipocytes in
response to insulin (Kim et al., 1998a). Additionally, ectopic ex-
pression of a dominant-negative SREBP1c was shown to inhibit
preadipocyte differentiation, while overexpression of this HLH
protein significantly enhances the adipogenic activity of PPARg
(Kim and Spiegelman, 1996). Expression of SREBP1c alone,
however, is only capable of inducing adipogenesis to a modest
extent, and additional studies suggest that SREBP1c contrib-
utes to the production of PPARg ligands, thereby facilitating
the action of PPARg (Kim et al., 1998b). There have been other
investigations linking SREBP1c to the induction of PPARg1
through SREBP binding sites within the pparg1 and g3 pro-
moters (Fajas et al., 1999). Support for an additional pathway
regulating adipogenesis derives from recent investigations into
the function of STAT5 proteins. STAT5A and STAT5B facilitate
transmission of cytokine signaling to a host of target genes con-
trolling many functions in several cell types. Ablation of these
STATs in mice leads to a spectrum of pathological responses
primarily associated with absence of growth hormone and pro-
lactin signaling but also leads to a 5-fold reduction in adipose
tissue mass compared to that of wild-type animals (Teglund
et al., 1998). This phenotype could be due to the attenuation
of proadipogenic prolactin signaling; however, recent studies
suggest a direct role for STAT5 in adipogenesis. Specifically,
ectopic expression of STAT5A in nonadipogenic fibroblasts
induces preadipocyte differentiation, which includes activation
of PPARg activity as well as accumulation of multiple fat265
R E V I E WFigure 1. Induction of adipogenesis by a cascade of
transcription factors
Exposure of preadipocytes to a cocktail of adipo-
genic inducers comprised of insulin, glucocorticoids,
agents that elevate cAMP (isobutylmethylxanthine),
and fetal bovine serum activates expression of sev-
eral transcription factors that converge on PPARg.
PPARg then induces C/EBPa expression, and to-
gether, these factors oversee terminal adipogenesis.droplets (Floyd and Stephens, 2003). The mechanisms respon-
sible for this activity of STAT5A, however, are not known since
the direct target gene (or genes) has not been identified. There
have been human genetic studies, however, supporting a role
for STAT5 in regulating transcription from the pparg3 promoter
(Meirhaeghe et al., 2003).
An interesting series of investigations show that components
of the molecular clock might also have a role in regulating both
adipocyte formation and function. Specifically, MEFs lacking
BMAL1 (brain and muscle ARNT-like protein 1), a transcription
factor known to regulate circadian rhythm, fail to differentiate
into adipocytes, and ectopic expression of BMAL1 in these cells
restores adipogenesis (Shimba et al., 2005). Similarly, another
component of the molecular clock, Rev-erba, is induced by
BMAL1 and PPARg during adipogenesis in 3T3-L1 preadipo-
cytes and facilitates expression of several adipogenic genes
(Fontaine et al., 2003; Shimba et al., 2005). A model for the tran-
scriptional cascade regulating adipogenesis is illustrated in Fig-
ure 1, including those factors that induce expression or activity
of other adipogenic transcription factors.
Role of clonal expansion and cell-cycle-related proteins
in regulating adipogenesis
It is generally thought that clonal expansion of a population of
preadipocytes is a prerequisite for their subsequent differentia-
tion into adipocytes. Adipogenesis is induced in a confluent
population of the cells by exposure to insulin, inducers of
cAMP signaling, and glucocorticoids in 10% FBS. This medium,
rich in mitogens, induces the entire population of cells to reenter
the cell cycle (G0 to G1) and undergo at least two rounds of cell
division before proceeding into terminal adipogenesis. Inhibition
of cell proliferation with drugs that block S phase prevents adi-
pogenesis, and it has therefore been suggested that adipogen-
esis requires mitosis to reorganize chromatin to facilitate induc-
tion of the adipogenic genes (Tang et al., 2003). Alternatively,
the necessity for the clonal expansion phase may be due to a266requirement for components of the cell-cycle machinery in pro-
moting adipogenic gene expression. As mentioned above,
Krox20 is an early growth response gene that is induced as con-
fluent preadipocytes reenter the cell cycle and also plays a direct
role in inducing C/EBPb and PPARg2 expression. The most no-
table cell-cycle proteins that regulate the adipogenic program
are the E2F family of transcription factors and associated pocket
proteins.
E2Fs, pocket proteins, and adipogenesis
Studies by Auwerx and associates have provided evidence sug-
gesting that the E2F family of transcription factors regulate adi-
pocyte differentiation (Fajas et al., 2002b). The data show that
E2F1-3 and E2F4 have opposing effects on differentiation,
which appears to be due to their differential regulation of pparg1
expression. In confluent preadipocytes, E2F4 represses PPARg
transcription through association with the pocket protein p130
and recruitment of the histone deacetylase HDAC3 to E2F re-
sponse elements in the promoter of pparg1. As preadipocytes
progress through clonal expansion, the abundance of E2F4/
p130 complexes subsides, while E2F1/Rb complexes appear.
Additionally, the cyclin-dependent kinase inhibitor p27KIP is
downregulated (Morrison and Farmer, 1999; Patel and Lane,
2000), thereby facilitating activation of cyclin D/Cdk4/6, which
corresponds with phosphorylation of Rb, resulting in the release
of E2F1 to induce transcription of pparg1 (see Figure 2). These
data demonstrating a function for E2Fs in adipogenesis corre-
late with a series of genetic studies performed in mice. E2F12/2
mice have a limited ability to accumulate adipose tissue in re-
sponse to high-fat feeding, while E2F42/2 ES cells contribute
more significantly to adipose tissue development than other
tissues of chimeric mice. Consistent with the mouse models,
E2F12/2 MEFs have a reduced capacity to differentiate into
adipocytes, whereas E2F4-deficient MEFs and ES cells express
an enhanced capacity for differentiation. Furthermore, the com-
bined loss of the major E2F4-associated pocket proteins p107
and p130 leads to enhanced adipogenesis in correspondingCELL METABOLISM : OCTOBER 2006
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adipogenesis
An alternative pathway to that presented in Figure 1
exists whereby E2Fs and associated pocket proteins
regulate expression of PPARg1. Activation of
PPARg2 likely occurs through the induction of
C/EBPa by PPARg1, and C/EBPa then induces
PPARg2 expression. This model is consistent with
a role for clonal expansion in promoting adipogene-
sis. G0, G1, and S correspond to phases of the cell
cycle, while GD is a term used to define the growth-
arrested state of terminally differentiated cells.MEFs (Classon et al., 2000), supporting the notion that E2F4/
p107 or E2F4/p130 complexes and not E2F4 alone repress
pparg1 transcription. One would predict that a deficiency in
Rb would enhance adipogenesis by facilitating E2F1 activity;
however, Rb2/2 MEFs interestingly have a reduced capacity
for differentiation into white adipocytes (Classon et al., 2000).
This is likely due to the requirement of Rb in facilitating cell-cycle
exit as well as cooperation with C/EBPs to induce adipogenic
gene expression (Chen et al., 1996). It appears, therefore, that
the E2Fs and pocket proteins regulate two separate but parallel
pathways that result in the activation of PPARg1 and PPARg2
expression (Figure 2). Specifically, factors such as Rb, which
channel through C/EBPb, lead to PPARg2 production, whereas
factors that promote E2F1 activity lead to PPARg1 expression.
Since PPARg2 and not PPARg1 is considered to be the predom-
inant regulator of adipogenesis, factors such as E2F that con-
verge on PPARg1 need to have a means of enhancing PPARg2
expression. This process could be facilitated through C/EBPa
whereby PPARg1 induces C/EBPa, which in turn induces
PPARg2 expression (Wu et al., 1999; Zuo et al., 2006). Such a
process could explain the redundancy in mechanisms regulat-
ing PPARg2 expression in mice deficient in C/EBPb and
C/EBPd (Tanaka et al., 1997). In these mice, it is conceivable
that signals in the developing adipose depot act on E2F to stim-
ulate PPARg1, which then induces C/EBPa followed by PPARg2
without the need for expression of C/EBPb or C/EBPd.
Negative regulation of adipogenesis
The differentiation of mesenchymal stem cells along a particular
lineage is regulated by both induction of various transcriptional
activators and suppression of inhibitors. It is likely that the subtle
balance in the activity of positive versus negative effectors de-
termines whether adipogenesis proceeds within a particular
population of progenitor cells. This concept is well illustrated
by the studies of MacDougald and associates, who demon-
strated that activation of the Wnt signaling pathway inhibitsCELL METABOLISM : OCTOBER 2006the differentiation of mesenchymal stem cells into adipocytes
(Ross et al., 2000). Wnt signaling appears to favor differentiation
of progenitor cells into bone or muscle, as opposed to adipo-
cytes (Bennett et al., 2005). Wnts are a large family of extracel-
lular effectors secreted by many different cell types and play
a determining role during early development. The binding of var-
ious Wnts to corresponding Frizzled receptors and low-density
lipoprotein receptor-related proteins (LRPs) activates signaling
pathways that alter gene expression and cell function. The ca-
nonical Wnt pathway leads to mobilization of b-catenin into
the nucleus, where it coactivates the TCF/LEF family of tran-
scription factors. Exposure of preadipocytes to Wnts or ectopic
expression of a constitutively active form of b-catenin inhibits
adipogenesis by preventing induction of PPARg and C/EBPa
(Moldes et al., 2003; Ross et al., 2000). The precise mechanism
involved is not known, but it likely involves expression of TCF/
LEF target genes since expression of dominant-negative TCF
(dnTCF) partially rescues the inhibitory effects of Wnt (Ross
et al., 2000). Furthermore, expression of dnTCF causes sponta-
neous differentiation of preadipocytes, suggesting that the
canonical Wnt signaling pathway acts in progenitor cells to sup-
press adipogenesis. An attractive candidate for a TCF-induced
adipogenic inhibitor is cyclin D1 since its gene is a direct target
of Wnt signaling, which has been shown to antagonize PPARg
activity (Fu et al., 2005a; Wang et al., 2003). It is also possible
that b-catenin might contribute to the inhibition of PPARg activ-
ity through mechanisms other than those involving TCF/LEF (Liu
and Farmer, 2004; Liu et al., 2006), and it is worth noting that
conditional deletion of b-catenin in the mesenchyme of the
developing mouse results in a switch to adipogenesis in the
myometrium (Arango et al., 2005).
Several studies have demonstrated that multiple effectors at-
tenuate adipogenesis by compromising the activity of C/EBPb.
These observations not only identify the existence of negative
regulators but also support a role for C/EBPb in regulating pre-
adipocyte differentiation. A series of these negative regulators,267
R E V I E WFigure 3. Negative control of adipogenesis
Negative regulators inhibit expression of PPARg and
C/EBPa by attenuating the activity of components
of the cascade presented in Figure 1. Several of
these negative factors appear to converge on
C/EBPb, supporting its role as a principal regulator
of adipogenesis.including GATA2/3, ETO/MTG8, CHOP10, GILZ, and Delta-
interacting protein A (DIPA), are expressed in preadipocytes,
and their expression is downregulated during differentiation.
Ectopic expression of each of these proteins in preadipocytes
inhibits adipogenesis through antagonism of C/EBPb activity
and thereby prevents the induction of PPARg and C/EBPa
(Batchnarova et al., 1995; Bezy et al., 2005; Rochford et al.,
2004; Shi et al., 2003; Tong et al., 2000, 2005). It is worth noting
that the vitamin D receptor, which is induced early in adipogen-
esis (Fu et al., 2005b), blocks preadipocyte differentiation by
downregulating C/EBPb through mechanisms that possibly in-
volve induction of ETO/MTG8 (Blumberg et al., 2006). Similarly,
Hedgehog signaling, which is known to regulate vertebrate de-
velopment, plays a conserved role in inhibiting fat formation,
possibly by inducing expression of GATA2 (Suh et al., 2006).
Additionally, Notch signaling plays an important role in early
development, and the Notch target Hes-1 blocks adipogenesis
by mechanisms that possibly involve recruitment of members
of the Groucho/TLE family of corepressors (Ross et al., 2006;
Ross et al., 2004). Other investigators have hypothesized that
oxygen tensionmight control adipose tissue function by regulat-
ing adipogenesis (Swiersz et al., 2004). Specifically, Yun et al.
(2002) have demonstrated that hypoxia inhibits preadipocyte
differentiation through a mechanism that involves repression
of pparg expression by DEC1/Stra13. DEC1/Stra13 is amember
of the Drosophila hairy/Enhancer of split transcription repressor
family that is induced by hypoxia-inducible transcription
factor 1a (HIF-1a). Stra13 is also induced by retinoic acid (RA)
(Boudjelal et al., 1997) and, consequently, might also be the
mediator by which RA inhibits adipogenesis (Schwarz et al.,
1997).
As discussed above, insulin possesses significant proadipo-
genic activity in part by promoting expression of SREBP1c.
Studies performed in animals as well as in cell culture demon-
strate that insulin promotes adipogenesis by suppressing the
inhibitory activity of the forkhead transcription factor FoxO1.
Specifically, exposure of preadipocytes to insulin results in
AKT-dependent phosphorylation of FoxO1, preventing its trans-
location into the nucleus and subsequent inhibition of adipo-
genic gene expression. To identify mechanisms responsible268for this inhibitory activity, Accili and associates demonstrated
that a constitutively active FoxO1, which is insensitive to AKT
phosphorylation, inhibits the differentiation of 3T3-F422A prea-
dipocytes by arresting the cells in clonal expansion. This block
in the adipogenic progression is likely due to a FoxO1-associ-
ated induction of the cyclin-dependent kinase inhibitor p21CIP
(Nakae et al., 2003). In support of an inhibitory function for
FoxO1 in adipose tissue, additional studies showed that
FoxO1 haploinsufficiency (foxo1+/2) protects against diet-in-
duced insulin resistance and diabetes possibly by preventing
adipocyte hypertrophy (Nakae et al., 2003). It is interesting that
two additional members of the forkhead family, FoxA2 and
FoxC2, also attenuate adipogenesis upstream of PPARg (Davis
et al., 2004; Wolfrum et al., 2003).
It is important tomention that, while threemembers of the KLF
family are proadipogenic (KLF5, KLF6, and KLF15), at least one
KLF acts as a suppressor of adipogenesis. Specifically, KLF2/
lung Kruppel-like factor is abundantly expressed in adipose tis-
sue in preadipocytes, and its expression is downregulated dur-
ing adipogenesis (Banerjee et al., 2003; Wu et al., 2005). Ectopic
expression of KLF2 in preadipocytes inhibits pparg2 transcrip-
tion, possibly by binding to KLF regulatory elements in the
same region of pparg2 that facilitates the proadipogenic activity
of KLF5 (Banerjee et al., 2003; Oishi et al., 2005;Wu et al., 2005).
The involvement of the different negative regulators in control-
ling adipogenesis is illustrated in Figure 3.
Role of coregulators in controlling the adipogenic
transcription factors
All of the adipogenic transcription factors discussed above initi-
ate their corresponding programs of gene expression by binding
to response elements in target genes where they recruit appro-
priate coactivators following dissociation from corepressors.
Most of these adipogenic coregulators are ubiquitously ex-
pressed and employed by other transcription factors in multiple
cell types. Consequently, their selectivity in activating a specific
gene is primarily defined by the interaction with the transcription
factor that is docked on the response element within the pro-
moter/enhancer of the target gene.CELL METABOLISM : OCTOBER 2006
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There is evidence suggesting that C/EBPb can dock on the pro-
moters of c/ebpa and pparg prior to their activation during the
early phase of adipogenesis (Salma et al., 2006). Adipogenic ef-
fectors then facilitate association of the chromatin remodeling
complex SWI/SNF with C/EBPb on the pparg2 promoter (Salma
et al., 2004). Glucocorticoid receptors (GRs) along with PPARg
are responsible for dislodging an mSin3a/HDAC-1 complex
fromC/EBPb on the C/EBP response element in the c/ebpa pro-
moter (Wiper-Bergeron et al., 2003; Zuo et al., 2006). Similarly,
the adipogenic potential of C/EBPa depends on its interaction
with SWI/SNF, which occurs through interaction with the trans-
activation element III (TEIII) domain in C/EBPa. This interaction
mediates further association with TBP/TFIIB factors (Pedersen
et al., 2001). C/EBPa can also associate with CBP/p300, but
the precise role of this interaction during adipogenesis is not
known (Erickson et al., 2001). PPARg appears to be capable
of interacting with several different coregulators, which explains
how it functions to control expression of numerous gene pro-
grams in mature adipocytes. Notable among these coregulators
is PPARg coactivator 1a (PGC-1a), which coactivates a host of
transcription factors in addition to PPARg that collectively par-
ticipate in energy balance (Lin et al., 2005). During development,
PGC-1a and b regulate brown adipose formation by coactivat-
ing transcription factors including nuclear respiratory factor 1
(NRF-1) and PPARg that regulate thermogenesis and mitochon-
drial biogenesis (Lin et al., 2005; Uldry et al., 2006). During adi-
pogenesis, activation of most PPARg target genes involves an
elaborate process in which binding of PPARg to corresponding
ligands dislodges corepressor complexes (NCoR/SMRT with
HDAC3) and recruitment of members of the p160 family of coac-
tivators, usually TIF2 or SRC-1. Recent studies have shown that
these p160 coregulators might also possess some nonredun-
dant function since lack of TIF2 in mice decreases PPARg activ-
ity in WAT and reduces fat accumulation. In BAT, the absence of
TIF2 facilitates an interaction between SRC-1 and PGC-1a lead-
ing to an increase in thermogenic activity. Interestingly, TIF22/2
mice are protected against obesity and display enhanced adap-
tive thermogenesis, whereas SRC-12/2 mice are prone to
obesity (Picard et al., 2002). The association of PPARg with
the p160 coregulators leads to further recruitment of histone
acetyltransferases (HATs) that appropriately modify surrounding
chromatin, allowing the transcriptional machinery access to the
gene promoter. At present, most studies show that the p160 co-
activators interact with the AF-2 domain of PPARg in response
to binding of appropriate ligands such as troglitazone. It is likely
that other coactivators associate with the AF-1 domain at the N
terminus of PPARg. Investigations have shown that two homol-
ogous cofactors, p300 and CBP, bind to the N terminus of
PPARg2 in a ligand-independent manner, whereas binding to
the C terminus is dependent on a ligand (Gelman et al., 1999).
A possible role for CBP in regulating adipose tissue develop-
ment has been supported by studies of CBP heterozygous
mice, which show markedly reduced weight of adipose tissue
but not of other tissues (Yamauchi et al., 2002).
PPARg also communicates with the basal transcriptional
machinery through its interaction with a large multicomponent
Mediator complex that is required for adipogenesis. Specifically,
PPARg associates with the TRAP (thyroid hormone receptor-
associated protein) coactivator-Mediator complex through
binding to the TRAP220 subunit in a ligand-enhanced manner.CELL METABOLISM : OCTOBER 2006MEFs lacking TRAP220 are resistant to PPARg2-stimulated adi-
pogenesis, but not to MyoD-stimulated myogenesis (Ge et al.,
2002). These observations suggest that TRAP220 acts, via the
Mediator complex, as a PPARg2-selective coactivator; this
interaction participates in commitment of mesenchymal cells
along an adipogenic as opposed to myogenic lineage. This se-
lectivitymight also be facilitated by additional proteins that inter-
act with the PPARg-Mediator complex. Specifically, PPARg-
interacting protein (PRIP) can associate with CBP/p300 and
TRAP130 of the Mediator complex. Supporting this notion,
PRIP2/2 MEFs are also resistant to PPARg-induced adipogen-
esis (Qi et al., 2003). In addition, a recent study identified a novel
human TAF (TBP [TATA-binding protein]-associated factor),
hTAFII43 (TAF8), which is induced and sequestered within TFIID
complexes during adipogenesis in 3T3-L1 cells. Furthermore,
ectopic expression of a dominant-negative TAF8 blocks 3T3-
L1 preadipocyte differentiation (Guermah et al., 2003).
Corepressors
Both NCoR and SMRT appear to function as negative modula-
tors of PPARg activity during adipogenesis since RNAi knock-
down of these factors in 3T3-L1 cells leads to increased expres-
sion of PPARg target genes and increased production of lipid
droplets (Yu et al., 2005). Studies also suggest that Rb functions
in a fashion similar to these corepressors by facilitating the
docking of HDAC3 on PPARg-driven promoters (Fajas et al.,
2002a). Interestingly, other studies suggest that Rb acts as amo-
lecular switch promoting brown versus white adipocyte forma-
tion (Hansen et al., 2004a, 2004b). In contrast, the corepressor
protein RIP140 appears to function in regulating development
of adipose tissue favoring a white phenotype. Specifically,
mice devoid of RIP140 are lean, show resistance to high-fat-
diet-induced obesity, and have increased oxygen consumption
(Leonardsson et al., 2004). It appears that this phenotype stems
from the capacity of RIP140 to suppress transcription factors
regulating oxidative metabolism and mitochondrial biogenesis,
characteristics of brown fat cells (Christian et al., 2005; Leo-
nardsson et al., 2004; Powelka et al., 2006).
As mentioned above, deacetylases that modify histones as
well as regulate activity of transcription factors are critical com-
ponents of various corepressor complexes. The HDACs partic-
ipate in adipogenic regulation, illustrated by the suppression of
C/EBPb and PPARg by HDAC1 and HDAC3, respectively. In-
duction of adipogenesis includes dislodgement of these HDACs
from their respective transcription factors by mechanisms that
include their degradation in the 26S proteasome, and it is likely
that the programmed turnover of these HDACs is an integral part
of the adipogenic process (Yoo et al., 2006). Other deacetylases
that target factors other than the histones might affect adipogen-
esis by altering the acetylation of coregulators of PPARg. Specif-
ically, Sirt1, the mammalian ortholog of the yeast longevity gene
sir2, attenuates adipogenesis by repressing PPARg activity lead-
ing to fat mobilization in white adipocytes, which triggers lipolysis
(Picard et al., 2004). SIRT1 is a NAD-dependent protein deace-
tylase capable of monitoring cellular oxidative state and altering
the activity of nuclear regulators in response to metabolites and
nutrients (Imai et al., 2000; Rodgers et al., 2005). Repression of
PPARg activity appears to involve docking of SIRT1 with NcoR
and SMRT on the promoters of PPARg target genes in adipo-
cytes (Picard et al., 2004). The interplay between various coac-
tivators and corepressors in determining the differentiation of
white versus brown adipocytes is shown in Figure 4.269
R E V I E WFigure 4. Coregulators and adipogenesis
The activity of the adipogenic transcription factors is
regulated by association with various corepressors
(red boxes) or coactivators (green boxes) at different
stages of differentiation of both brown as well as
white preadipocytes. The Mediator shown to be as-
sociating with PPARg corresponds to the TRAP
(thyroid hormone receptor-associated protein) tran-
scriptional coactivator complex, which interacts
physically with PPARg through the TRAP220 sub-
unit. See text for detailed discussion of the participa-
tion of the various protein complexes in controlling
each of the transcription factors.Concluding remarks
In conclusion, it is quite apparent that significant progress has
been made during the last few years in identifying the transcrip-
tional processes controlling the differentiation of preadipocytes
into mature fat cells. The challenge for the future is to under-
stand the mechanisms governing the commitment of mesen-
chymal stem cells to the adipogenic lineage. There are certainly
some indications of possible players in this process; however,
the adipocyte field lags far behind that of other developmental
systems since it has been difficult to locate adipogenic progen-
itors during early development. Additionally, there is a dearth of
information concerning themechanisms that give rise to the var-
ious white fat depots. Recent studies have suggested that there
are significant differences between subcutaneous and visceral
depots, particularly with regard to their role in cardiovascular
disease and diabetes. The reasons for these differences are es-
sentially unknown. It is possible that each of the depots arises
from different progenitors controlled by a separate set of tran-
scriptional processes, resulting in distinct depot-specific adipo-
cytes. Future research will no doubt address some of these
questions by investigating the role of developmental cues
shown to participate in the formation of other tissues. Finally,
most of what we know has come from studies of rodents either
in vivo or in cell culture. There are examples of adipose function
that do not translate from the mouse to the human; conse-
quently, attention needs to be given to understanding the tran-
scriptional control of adipocyte formation and function in human
adipose tissue.
Acknowledgments
I am grateful to past and present members of my group who have con-
tributed to the studies referenced in this review. I am particularly grateful
to Dr. Kathryn Davis for valuable suggestions and constructive criticism.
I am supported by National Institutes of Health grants DK51586 and
DK58825.270References
Arango, N.A., Szotek, P.P., Manganaro, T.F., Oliva, E., Donahoe, P.K., and
Teixeira, J. (2005). Conditional deletion of beta-catenin in the mesenchyme
of the developing mouse uterus results in a switch to adipogenesis in the
myometrium. Dev. Biol. 288, 276–283.
Banerjee, S.S., Feinberg, M.W., Watanabe, M., Gray, S., Haspel, R.L., Den-
kinger, D.J., Kawahara, R., Hauner, H., and Jain, M.K. (2003). The Kruppel-
like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma
expression and adipogenesis. J. Biol. Chem. 278, 2581–2584.
Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R.,
Koder, A., and Evans, R.M. (1999). PPAR gamma is required for placental,
cardiac, and adipose tissue development. Mol. Cell 4, 585–595.
Batchnarova, N., Wang, X.-Z., and Ron, D. (1995). Inhibition of adipogenesis
by the stress-induced protein CHOP (Gadd153). EMBO J. 14, 4654–4661.
Bennett, C.N., Longo, K.A., Wright, W.S., Suva, L.J., Lane, T.F., Hankenson,
K.D., and MacDougald, O.A. (2005). Regulation of osteoblastogenesis and
bone mass by Wnt10b. Proc. Natl. Acad. Sci. USA 102, 3324–3329.
Bezy, O., Elabd, C., Cochet, O., Petersen, R.K., Kristiansen, K., Dani, C., Ail-
haud, G., and Amri, E.Z. (2005). Delta-interacting protein A, a new inhibitory
partner of CCAAT/enhancer-binding protein beta, implicated in adipocyte
differentiation. J. Biol. Chem. 280, 11432–11438.
Blumberg, J.M., Tzameli, I., Astapova, I., Lam, F.S., Flier, J.S., and Hollen-
berg, A.N. (2006). Complex role of the vitamin D receptor and its ligand in
adipogenesis in 3T3-L1 cells. J. Biol. Chem. 281, 11205–11213.
Boudjelal, M., Taneja, R., Matsubara, S., Bouillet, P., Dolle, P., andChambon,
P. (1997). Overexpression of Stra13, a novel retinoic acid-inducible gene of
the basic helix-loop-helix family, inhibitsmesodermal and promotes neuronal
differentiation of P19 cells. Genes Dev. 11, 2052–2065.
Cao, Z., Umek, R.M., and McKnight, S.L. (1991). Regulated expression of
three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes
Dev. 5, 1538–1552.
Chen, P.L., Riley, D.J., Chen, Y., and Lee, W.H. (1996). Retinoblastoma pro-
tein positively regulates terminal adipocyte differentiation through direct in-
teraction with C/EBPs. Genes Dev. 10, 2794–2804.CELL METABOLISM : OCTOBER 2006
R E V I E WChen, Z., Torrens, J.I., Anand, A., Spiegelman, B.M., and Friedman, J.M.
(2005). Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -in-
dependent mechanisms. Cell Metab. 1, 93–106.
Christian, M., Kiskinis, E., Debevec, D., Leonardsson, G., White, R., and
Parker, M.G. (2005). RIP140-targeted repression of gene expression in adi-
pocytes. Mol. Cell. Biol. 25, 9383–9391.
Christy, R.J., Kaestner, K.H., Geiman, D.E., and Lane, M.D. (1991). CCAAT/
enhancer binding protein gene promoter: binding of nuclear factors during
differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA 88,
2593–2597.
Clarke, S.L., Robinson, C.E., and Gimble, J.M. (1997). CAAT/enhancer bind-
ing proteins directly modulate transcription from the peroxisome proliferator-
activated receptor gamma2 promoter. Biochem. Biophys. Res. Commun.
240, 99–103.
Classon, M., Kennedy, B.K., Mulloy, R., and Harlow, E. (2000). Opposing
roles of pRB and p107 in adipocyte differentiation. Proc. Natl. Acad. Sci.
USA 97, 10826–10831.
Davis, K.E., Moldes, M., and Farmer, S.R. (2004). The forkhead transcription
factor FoxC2 inhibits white adipocyte differentiation. J. Biol. Chem. 279,
42453–42461.
El-Jack, A.K., Hamm, J.K., Pilch, P.F., and Farmer, S.R. (1999). Reconstitu-
tion of insulin-sensitive glucose transport in fibroblasts requires expression
of both PPARg and C/EBPa. J. Biol. Chem. 274, 7946–7951.
Erickson, R.L., Hemati, N., Ross, S.E., and MacDougald, O.A. (2001). p300
coactivates the adipogenic transcription factor CCAAT/enhancer-binding
protein alpha. J. Biol. Chem. 276, 16348–16355.
Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A.M., Saladin, R.,
Najib, J., Laville, M., Fruchart, J.C., Deeb, S., et al. (1997). The organization,
promoter analysis, and expression of the human PPARgamma gene. J. Biol.
Chem. 272, 18779–18789.
Fajas, L., Schoonjans, K., Gelman, L., Kim, J.B., Najib, J., Martin, G., Fru-
chart, J.C., Briggs, M., Spiegelman, B.M., and Auwerx, J. (1999). Regulation
of peroxisome proliferator-activated receptor gamma expression by adipo-
cyte differentiation and determination factor 1/sterol regulatory element
binding protein 1: implications for adipocyte differentiation and metabolism.
Mol. Cell. Biol. 19, 5495–5503.
Fajas, L., Egler, V., Reiter, R., Hansen, J., Kristiansen, K., Debril, M.B., Miard,
S., and Auwerx, J. (2002a). The retinoblastoma-histone deacetylase 3
complex inhibits PPARgamma and adipocyte differentiation. Dev. Cell 3,
903–910.
Fajas, L., Landsberg, R.L., Huss-Garcia, Y., Sardet, C., Lees, J.A., and Au-
werx, J. (2002b). E2Fs regulate adipocyte differentiation. Dev. Cell 3, 39–49.
Floyd, Z.E., and Stephens, J.M. (2003). STAT5A promotes adipogenesis in
nonprecursor cells and associates with the glucocorticoid receptor during
adipocyte differentiation. Diabetes 52, 308–314.
Fontaine, C., Dubois, G., Duguay, Y., Helledie, T., Vu-Dac, N., Gervois, P.,
Soncin, F., Mandrup, S., Fruchart, J.C., Fruchart-Najib, J., and Staels, B.
(2003). The orphan nuclear receptor Rev-Erbalpha is a peroxisome prolifera-
tor-activated receptor (PPAR) gamma target gene and promotes PPAR-
gamma-induced adipocyte differentiation. J. Biol. Chem. 278, 37672–37680.
Freytag, S.O., Paielli, D.L., and Gilbert, J.D. (1994). Ectopic expression of the
CCAAT/enhancer-binding protein alpha promotes the adipogenic program in
a variety of mouse fibroblastic cells. Genes Dev. 8, 1654–1663.
Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T.P., and
Pestell, R.G. (2005a). Cyclin D1 inhibits peroxisome proliferator-activated re-
ceptor gamma-mediated adipogenesis through histone deacetylase recruit-
ment. J. Biol. Chem. 280, 16934–16941.
Fu, M., Sun, T., Bookout, A.L., Downes, M., Yu, R.T., Evans, R.M., and Man-
gelsdorf, D.J. (2005b). A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. Mol.
Endocrinol. 19, 2437–2450.
Ge, K., Guermah, M., Yuan, C.X., Ito, M., Wallberg, A.E., Spiegelman, B.M.,
and Roeder, R.G. (2002). Transcription coactivator TRAP220 is required for
PPAR gamma 2-stimulated adipogenesis. Nature 417, 563–567.CELL METABOLISM : OCTOBER 2006Gelman, L., Zhou, G., Fajas, L., Raspe, E., Fruchart, J.C., and Auwerx, J.
(1999). p300 interacts with the N- and C-terminal part of PPARgamma2 in a
ligand-independent and -dependent manner, respectively. J. Biol. Chem.
274, 7681–7688.
Green, H., and Kehinde, O. (1975). An established preadipose cell line and its
differentiation in culture. II. Factors affecting the adipose conversion. Cell 5,
19–27.
Green, H., and Kehinde, O. (1976). Spontaneous heritable changes leading to
increased adipose conversion in 3T3 cells. Cell 7, 105–113.
Guermah, M., Ge, K., Chiang, C.M., and Roeder, R.G. (2003). The TBN pro-
tein, which is essential for early embryonic mouse development, is an induc-
ible TAFII implicated in adipogenesis. Mol. Cell 12, 991–1001.
Hamm, J.K., Park, B.H., and Farmer, S.R. (2001). A role for C/EBPbeta in reg-
ulating peroxisome proliferator-activated receptor gamma activity during
adipogenesis in 3T3-L1 preadipocytes. J. Biol. Chem. 276, 18464–18471.
Hansen, J.B., Jorgensen, C., Petersen, R.K., Hallenborg, P., De Matteis, R.,
Boye, H.A., Petrovic, N., Enerback, S., Nedergaard, J., Cinti, S., et al. (2004a).
Retinoblastoma protein functions as a molecular switch determining white
versus brown adipocyte differentiation. Proc. Natl. Acad. Sci. USA 101,
4112–4117.
Hansen, J.B., te Riele, H., and Kristiansen, K. (2004b). Novel function of the
retinoblastoma protein in fat: regulation of white versus brown adipocyte dif-
ferentiation. Cell Cycle 3, 774–778.
Imai, S., Armstrong, C.M., Kaeberlein, M., andGuarente, L. (2000). Transcrip-
tional silencing and longevity protein Sir2 is an NAD-dependent histone de-
acetylase. Nature 403, 795–800.
Kim, J.B., and Spiegelman, B.M. (1996). ADD1/SREBP1 promotes adipocyte
differentiation and gene expression linked to fatty acid metabolism. Genes
Dev. 10, 1096–1107.
Kim, J.B., Sarraf, P., Wright, M., Yao, K.M., Mueller, E., Solanes, G., Lowell,
B.B., and Spiegelman, B.M. (1998a). Nutritional and insulin regulation of fatty
acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin.
Invest. 101, 1–9.
Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. (1998b). ADD1/
SREBP1 activates PPAR gamma through the production of endogenous
ligand. Proc. Natl. Acad. Sci. USA 95, 4333–4337.
Koutnikova, H., Cock, T.A., Watanabe, M., Houten, S.M., Champy, M.F., Di-
erich, A., and Auwerx, J. (2003). Compensation by the muscle limits the met-
abolic consequences of lipodystrophy in PPAR gamma hypomorphic mice.
Proc. Natl. Acad. Sci. USA 100, 14457–14462.
Leonardsson, G., Steel, J.H., Christian, M., Pocock, V., Milligan, S., Bell, J.,
So, P.W., Medina-Gomez, G., Vidal-Puig, A., White, R., and Parker, M.G.
(2004). Nuclear receptor corepressor RIP140 regulates fat accumulation.
Proc. Natl. Acad. Sci. USA 101, 8437–8442.
Li, D., Yea, S., Li, S., Chen, Z., Narla, G., Banck, M., Laborda, J., Tan, S.,
Friedman, J.M., Friedman, S.L., and Walsh, M.J. (2005). Kruppel-like fac-
tor-6 promotes preadipocyte differentiation through histone deacetylase
3-dependent repression of DLK1. J. Biol. Chem. 280, 26941–26952.
Lin, J., Handschin, C., and Spiegelman, B.M. (2005). Metabolic control
through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361–
370.
Linhart, H.G., Ishimura-Oka, K., DeMayo, F., Kibe, T., Repka, D., Poindexter,
B., Bick, R.J., and Darlington, G.J. (2001). C/EBPalpha is required for differ-
entiation of white, but not brown, adipose tissue. Proc. Natl. Acad. Sci. USA
98, 12532–12537.
Liu, J., and Farmer, S.R. (2004). Regulating the balance between peroxisome
proliferator-activated receptor gamma and beta-catenin signaling during
adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective
mutant of beta-catenin inhibits expression of a subset of adipogenic genes.
J. Biol. Chem. 279, 45020–45027.
Liu, J., Wang, H., Zuo, Y., and Farmer, S.R. (2006). A functional interaction
between PPARgamma and beta-catenin. Mol. Cell. Biol. 26, 5827–5837.271
R E V I E WMeirhaeghe, A., Fajas, L., Gouilleux, F., Cottel, D., Helbecque, N., Auwerx, J.,
and Amouyel, P. (2003). A functional polymorphism in a STAT5B site of the
human PPAR gamma 3 gene promoter affects height and lipid metabolism
in a French population. Arterioscler. Thromb. Vasc. Biol. 23, 289–294.
Moldes, M., Zuo, Y., Morrison, R.F., Silva, D., Park, B.H., Liu, J., and Farmer,
S.R. (2003). Peroxisome-proliferator-activated receptor gamma suppresses
Wnt/beta-catenin signalling during adipogenesis. Biochem. J. 376, 607–613.
Mori, T., Sakaue, H., Iguchi, H., Gomi, H., Okada, Y., Takashima, Y., Naka-
mura, K., Nakamura, T., Yamauchi, T., Kubota, N., et al. (2005). Role of Krup-
pel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J. Biol.
Chem. 280, 12867–12875.
Morrison, R.F., and Farmer, S.R. (1999). Role of PPARgamma in regulating
a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c)
and p21(Waf1/Cip1), during adipogenesis. J. Biol. Chem. 274, 17088–17097.
Mueller, E., Drori, S., Aiyer, A., Yie, J., Sarraf, P., Chen, H., Hauser, S., Rosen,
E.D., Ge, K., Roeder, R.G., and Spiegelman, B.M. (2002). Genetic analysis of
adipogenesis through peroxisome proliferator-activated receptor gamma
isoforms. J. Biol. Chem. 277, 41925–41930.
Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W.H., III, Arden, K.C., and Accili,
D. (2003). The forkhead transcription factor Foxo1 regulates adipocyte differ-
entiation. Dev. Cell 4, 119–129.
Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura,
G., Maemura, K., Yamauchi, T., Kubota, N., et al. (2005). Kruppel-like tran-
scription factor KLF5 is a key regulator of adipocyte differentiation. Cell
Metab. 1, 27–39.
Park, B.-H., Qiang, L., and Farmer, S.R. (2004). Phosphorylation of C/EBP-
beta at a consensus ERK/GSK3 site is required for the induction of adipo-
nectin gene expression during the differentiation of mouse fibroblasts into
adipocytes. Mol. Cell. Biol. 24, 8671–8680.
Patel, Y.M., and Lane,M.D. (2000). Mitotic clonal expansion during preadipo-
cyte differentiation: calpain-mediated turnover of p27. J. Biol. Chem. 275,
17653–17660.
Pedersen, T.A., Kowenz-Leutz, E., Leutz, A., and Nerlov, C. (2001). Cooper-
ation between C/EBPalpha TBP/TFIIB and SWI/SNF recruiting domains is
required for adipocyte differentiation. Genes Dev. 15, 3208–3216.
Picard, F., Gehin, M., Annicotte, J., Rocchi, S., Champy, M.F., O’Malley,
B.W., Chambon, P., and Auwerx, J. (2002). SRC-1 and TIF2 control energy
balance between white and brown adipose tissues. Cell 111, 931–941.
Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Ma-
chado De Oliveira, R., Leid, M., McBurney, M.W., and Guarente, L. (2004).
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-
gamma. Nature 429, 771–776.
Powelka, A.M., Seth, A., Virbasius, J.V., Kiskinis, E., Nicoloro, S.M., Guil-
herme, A., Tang, X., Straubhaar, J., Cherniack, A.D., Parker, M.G., and
Czech, M.P. (2006). Suppression of oxidative metabolism and mitochondrial
biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes.
J. Clin. Invest. 116, 125–136.
Qi, C., Surapureddi, S., Zhu, Y.J., Yu, S., Kashireddy, P., Rao, M.S., and
Reddy, J.K. (2003). Transcriptional coactivator PRIP, the peroxisome prolif-
erator-activated receptor gamma (PPARgamma)-interacting protein, is re-
quired for PPARgamma-mediated adipogenesis. J. Biol. Chem. 278,
25281–25284.
Rochford, J.J., Semple, R.K., Laudes, M., Boyle, K.B., Christodoulides, C.,
Mulligan, C., Lelliott, C.J., Schinner, S., Hadaschik, D., Mahadevan, M.,
et al. (2004). ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator
of early adipogenesis. Mol. Cell. Biol. 24, 9863–9872.
Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puig-
server, P. (2005). Nutrient control of glucose homeostasis through a complex
of PGC-1alpha and SIRT1. Nature 434, 113–118.
Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S.,
Spiegelman, B.M., and Mortensen, R.M. (1999). PPAR gamma is required
for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611–
617.272Rosen, E.D., Hsu, C.H., Wang, X., Sakai, S., Freeman, M.W., Gonzalez, F.J.,
and Spiegelman, B.M. (2002). C/EBPalpha induces adipogenesis through
PPARgamma: a unified pathway. Genes Dev. 16, 22–26.
Ross, D.A., Rao, P.K., and Kadesch, T. (2004). Dual roles for the Notch target
gene Hes-1 in the differentiation of 3T3-L1 preadipocytes. Mol. Cell. Biol. 24,
3505–3513.
Ross, D.A., Hannenhalli, S., Tobias, J.W., Cooch, N., Shiekhattar, R., and Ka-
desch, T. (2006). Functional analysis of Hes-1 in preadipocytes. Mol. Endo-
crinol. 20, 698–705.
Ross, S.E., Hemati, N., Longo, K.A., Bennett, C.N., Lucas, P.C., Erickson,
R.L., andMacDougald, O.A. (2000). Inhibition of adipogenesis byWnt signal-
ing. Science 289, 950–953.
Salma, N., Xiao, H., Mueller, E., and Imbalzano, A.N. (2004). Temporal recruit-
ment of transcription factors and SWI/SNF chromatin-remodeling enzymes
during adipogenic induction of the peroxisome proliferator-activated recep-
tor gamma nuclear hormone receptor. Mol. Cell. Biol. 24, 4651–4663.
Salma, N., Xiao, H., and Imbalzano, A.N. (2006). Temporal recruitment of
CCAAT/enhancer-binding proteins to early and late adipogenic promoters
in vivo. J. Mol. Endocrinol. 36, 139–151.
Schwarz, E.J., Reginato, M.J., Shao, D., Krakow, S.L., and Lazar, M.A.
(1997). Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated
transcription. Mol. Cell. Biol. 17, 1552–1561.
Shi, X., Shi, W., Li, Q., Song, B., Wan, M., Bai, S., and Cao, X. (2003). A glu-
cocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of
mesenchymal cells. EMBO Rep. 4, 374–380.
Shimba, S., Ishii, N., Ohta, Y., Ohno, T., Watabe, Y., Hayashi, M., Wada, T.,
Aoyagi, T., and Tezuka, M. (2005). Brain and muscle Arnt-like protein-1
(BMAL1), a component of the molecular clock, regulates adipogenesis.
Proc. Natl. Acad. Sci. USA 102, 12071–12076.
Soukas, A., Socci, N.D., Saatkamp, B.D., Novelli, S., and Friedman, J.M.
(2001). Distinct transcriptional profiles of adipogenesis in vivo and in vitro.
J. Biol. Chem. 276, 34167–34174.
Suh, J.M., Gao, X., McKay, J., McKay, R., Salo, Z., and Graff, J.M. (2006).
Hedgehog signaling plays a conserved role in inhibiting fat formation. Cell
Metab. 3, 25–34.
Swiersz, L.M., Giaccia, A.J., and Yun, Z. (2004). Oxygen-dependent regula-
tion of adipogenesis. Methods Enzymol. 381, 387–395.
Tanaka, T., Yoshida, N., Kishimoto, T., and Akira, S. (1997). Defective adipo-
cyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene.
EMBO J. 16, 7432–7443.
Tang, Q.Q., and Lane, M.D. (1999). Activation and centromeric localization of
CCAAT/enhancer-binding proteins during themitotic clonal expansion of ad-
ipocyte differentiation. Genes Dev. 13, 2231–2241.
Tang, Q.Q., Otto, T.C., and Lane, M.D. (2003). Mitotic clonal expansion:
a synchronous process required for adipogenesis. Proc. Natl. Acad. Sci.
USA 100, 44–49.
Tang, Q.Q., Gronborg, M., Huang, H., Kim, J.W., Otto, T.C., Pandey, A., and
Lane, M.D. (2005). Sequential phosphorylation of CCAAT enhancer-binding
protein beta by MAPK and glycogen synthase kinase 3beta is required for
adipogenesis. Proc. Natl. Acad. Sci. USA 102, 9766–9771.
Teglund, S., McKay, C., Schuetz, E., van Deursen, J.M., Stravopodis, D.,
Wang, D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J.N. (1998). Stat5a
and Stat5b proteins have essential and nonessential, or redundant, roles in
cytokine responses. Cell 93, 841–850.
Tong, Q., Dalgin, G., Xu, H., Ting, C.N., Leiden, J.M., and Hotamisligil, G.S.
(2000). Function of GATA transcription factors in preadipocyte-adipocyte
transition. Science 290, 134–138.
Tong, Q., Tsai, J., Tan, G., Dalgin, G., and Hotamisligil, G.S. (2005). Interac-
tion between GATA and the C/EBP family of transcription factors is critical in
GATA-mediated suppression of adipocyte differentiation. Mol. Cell. Biol. 25,
706–715.CELL METABOLISM : OCTOBER 2006
R E V I E WTontonoz, P., Graves, R.A., Budavari, A.I., Erdjument-Bromage, H., Lui, M.,
Hu, E., Tempst, P., and Spiegelman, B.M. (1994a). Adipocyte-specific tran-
scription factor ARF6 is a heterodimeric complex of two nuclear hormone
receptors, PPAR gamma and RXR alpha. Nucleic Acids Res. 22, 5628–5634.
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M.
(1994b). mPPARg2: tissue-specific regulator of an adipocyte enhancer.
Genes Dev. 8, 1224–1234.
Tontonoz, P., Hu, E., and Spiegelman, B.M. (1994c). Stimulation of adipo-
genesis in fibroblasts by PPARg, a lipid-activated transcription factor. Cell
79, 1147–1156.
Uldry, M., Yang, W., St-Pierre, J., Lin, J., Seale, P., and Spiegelman, B.
(2006). Complementary action of the PGC-1 coactivators in mitochondrial
biogenesis and brown fat differentiation. Cell Metab. 3, 333–341.
Wang, C., Pattabiraman, N., Zhou, J.N., Fu, M., Sakamaki, T., Albanese, C.,
Li, Z., Wu, K., Hulit, J., Neumeister, P., et al. (2003). Cyclin D1 repression of
peroxisome proliferator-activated receptor gamma expression and transac-
tivation. Mol. Cell. Biol. 23, 6159–6173.
Wang, N.D., Finegold, M.J., Bradley, A., Ou, C.N., Abdelsayed, S.V., Wilde,
M.D., Taylor, L.R., Wilson, D.R., and Darlington, G.J. (1995). Impaired energy
homeostasis in C/EBP alpha knockout mice. Science 269, 1108–1112.
Wiper-Bergeron, N., Wu, D., Pope, L., Schild-Poulter, C., and Hache, R.J.
(2003). Stimulation of preadipocyte differentiation by steroid through target-
ing of an HDAC1 complex. EMBO J. 22, 2135–2145.
Wolfrum, C., Shih, D.Q., Kuwajima, S., Norris, A.W., Kahn, C.R., and Stoffel,
M. (2003). Role of Foxa-2 in adipocyte metabolism and differentiation. J. Clin.
Invest. 112, 345–356.
Wu, J., Srinivasan, S.V., Neumann, J.C., and Lingrel, J.B. (2005). The KLF2
transcription factor does not affect the formation of preadipocytes but in-
hibits their differentiation into adipocytes. Biochemistry 44, 11098–11105.
Wu, Z., Xie, Y., Bucher, N.L.R., and Farmer, S.R. (1995). Conditional ectopic
expression of C/EBPb in NIH-3T3 cells induces PPARg and stimulates adipo-
genesis. Genes Dev. 9, 2350–2363.
Wu, Z., Bucher, N.L.R., and Farmer, S.R. (1996). Induction of peroxisome
proliferator-activated receptor gamma during conversion of 3T3 fibroblastsCELL METABOLISM : OCTOBER 2006into adipocytes is mediated by C/EBPb, C/EBPd and glucocorticoids. Mol.
Cell. Biol. 16, 4128–4136.
Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmont, G., Troy, A.E., McKeon,
C., Darlington, G.J., and Spiegelman, B.M. (1999). Cross-regulation of C/
EBPa and PPARg controls the transcriptional pathway of adipogenesis
and insulin sensitivity. Mol. Cell 3, 151–158.
Yamauchi, T., Oike, Y., Kamon, J., Waki, H., Komeda, K., Tsuchida, A., Date,
Y., Li, M.X., Miki, H., Akanuma, Y., et al. (2002). Increased insulin sensitivity
despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet. 30, 221–
226.
Yeh, W.C., Cao, Z., Classon, M., and McKnight, S.L. (1995). Cascade regu-
lation of terminal adipocyte differentiation by three members of the C/EBP
family of leucine zipper proteins. Genes Dev. 9, 168–181.
Yoo, E.J., Chung, J.J., Choe, S.S., Kim, K.H., and Kim, J.B. (2006). Down-
regulation of histone deacetylases stimulates adipocyte differentiation. J.
Biol. Chem. 281, 6608–6615.
Yu, C., Markan, K., Temple, K.A., Deplewski, D., Brady, M.J., and Cohen,
R.N. (2005). The nuclear receptor corepressors NCoR and SMRT decrease
peroxisome proliferator-activated receptor gamma transcriptional activity
and repress 3T3-L1 adipogenesis. J. Biol. Chem. 280, 13600–13605.
Yun, Z., Maecker, H.L., Johnson, R.S., and Giaccia, A.J. (2002). Inhibition of
PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13:
a mechanism for regulation of adipogenesis by hypoxia. Dev. Cell 2, 331–
341.
Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D.,
Liang, J., Li, E., et al. (2004a). Selective disruption of PPARgamma 2 impairs
the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad.
Sci. USA 101, 10703–10708.
Zhang, J.W., Klemm, D.J., Vinson, C., and Lane, M.D. (2004b). Role of CREB
in transcriptional regulation of CCAAT/enhancer-binding protein beta gene
during adipogenesis. J. Biol. Chem. 279, 4471–4478.
Zuo, Y., Qiang, L., and Farmer, S.R. (2006). Activation of C/EBPalpha expres-
sion by C/EBPbeta during adipogenesis requires a PPARgamma-associated
repression of HDAC1 at the C/EBPalpha gene promoter. J. Biol. Chem. 281,
7960–7967.273
